Fig. 3.

Percentage of ICOS⁺ T cell subsets before and during aPD-1/CTLA-4 combination therapy

(a, b, c) Percentage of ICOS⁺ CD 4 T-cell subsets (TCM p = 0.002, TEM p = 0.003, TEMRA p = 0.004) (a), Tregs subsets (b) and CD8 T-cell subsets (TCM p =  0.003, TEM p = 0.012) (c) respectively, at screening and on-treatment time points. (d, e, f) Comparison between responding (R) and non-responding (NR) patients for the percentage of ICOS⁺ CD 4 T-cell subsets (TN NR p = 0.01, TCM NR p = 0.02, TEM NR p = 0.03, TEMRA NR p = 0.01 (d), Tregs subsets (nTreg NR p = 0.01) (e) and CD8 T-cell subsets (TCM R p = 0.03) (f) respectively, at screening and on-treatment time points. Paired samples are shown connected by black lines in each graph. Significance (Wilcoxon signed-rank test) is shown in each graph, with * p < 0.05 and ** p < 0.01. P values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate